JP2013512877A5 - - Google Patents

Download PDF

Info

Publication number
JP2013512877A5
JP2013512877A5 JP2012541498A JP2012541498A JP2013512877A5 JP 2013512877 A5 JP2013512877 A5 JP 2013512877A5 JP 2012541498 A JP2012541498 A JP 2012541498A JP 2012541498 A JP2012541498 A JP 2012541498A JP 2013512877 A5 JP2013512877 A5 JP 2013512877A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
administration
growth factor
fgf
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012541498A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013512877A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/068700 external-priority patent/WO2011067317A1/en
Publication of JP2013512877A publication Critical patent/JP2013512877A/ja
Publication of JP2013512877A5 publication Critical patent/JP2013512877A5/ja
Withdrawn legal-status Critical Current

Links

JP2012541498A 2009-12-02 2010-12-02 幹細胞の刺激のための医薬組成物 Withdrawn JP2013512877A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2009066251 2009-12-02
EPPCT/EP2009/066251 2009-12-02
PCT/EP2010/068700 WO2011067317A1 (en) 2009-12-02 2010-12-02 Pharmaceutical compositions for the stimulation of stem cells.

Publications (2)

Publication Number Publication Date
JP2013512877A JP2013512877A (ja) 2013-04-18
JP2013512877A5 true JP2013512877A5 (https=) 2014-02-13

Family

ID=42316097

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012541498A Withdrawn JP2013512877A (ja) 2009-12-02 2010-12-02 幹細胞の刺激のための医薬組成物

Country Status (12)

Country Link
JP (1) JP2013512877A (https=)
KR (1) KR20120099751A (https=)
CN (1) CN102711798A (https=)
AU (1) AU2010326633A1 (https=)
BR (1) BR112012013164A2 (https=)
CA (1) CA2781493A1 (https=)
IL (1) IL219901A0 (https=)
MX (1) MX2012005976A (https=)
NZ (1) NZ599930A (https=)
RU (1) RU2012120834A (https=)
TW (1) TW201141510A (https=)
WO (1) WO2011067317A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6538081B2 (ja) * 2014-07-07 2019-07-03 メディポスト カンパニー リミテッド 刺激を受けた幹細胞の馴化培地の発毛促進能およびそれらの使用
CN105079791A (zh) * 2015-09-18 2015-11-25 郑榆坤 一种刺激体内内源干细胞的组合物及其应用
RU2634576C1 (ru) * 2016-10-24 2017-10-31 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Способ стимуляции регенерации тканей
CN107050428B (zh) * 2017-03-23 2020-05-05 温州医科大学 Fgf20药物及其对脑创伤的治疗应用
CN107648592B (zh) * 2017-11-13 2021-05-14 深圳市喆邦生物工程有限公司 趋化因子ccl4作为制备治疗骨折药物的应用
RU2686718C1 (ru) * 2018-03-12 2019-04-30 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Средство, стимулирующее функции мезенхимальных клеток-предшественников in vitro
KR102106710B1 (ko) 2018-10-11 2020-05-04 강원대학교산학협력단 인간 전분화능 줄기세포로부터 조혈모세포 및 대식세포 분화 증진 방법
CN111195350A (zh) * 2020-01-15 2020-05-26 重庆大学 IGF1和IGF1Ec24联合在制备促进组织修复与再生的药物中的应用
WO2021187895A1 (ko) * 2020-03-17 2021-09-23 주식회사 히에라바이오 심장줄기세포를 포함하는 허혈성 질환의 예방 또는 치료용 조성물
CN111621525B (zh) * 2020-06-18 2021-04-23 中赛干细胞基因工程有限公司 Stx1b基因在促进人脂肪间充质干细胞生长和分化中的用途
KR20240131080A (ko) * 2023-02-23 2024-08-30 서울대학교산학협력단 배외내배엽 줄기세포의 배양용 배지 조성물
CN116836920B (zh) * 2023-08-21 2024-05-24 广东横琴粤澳深度合作区齐美国际干细胞医院有限公司 一种无血清培养基及其制备间充质干细胞的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1786471B1 (en) * 2004-07-30 2015-02-11 Mayo Foundation For Medical Education And Research Treating cardiovascular tissue
WO2006081190A2 (en) * 2005-01-25 2006-08-03 Five Prime Therapeutics, Inc. Compositions and methods for treating cardiac conditions
US9765298B2 (en) * 2006-07-24 2017-09-19 Mayo Foundation For Medical Education And Research Methods and materials for providing cardiac cells
US8481075B2 (en) * 2007-12-13 2013-07-09 Beijing Shengyiyao Science & Technology Development Co. Ltd. Preparation and application of biodegradable-material-made microsphere vascular embolus containing liposome-encapsulated cytokines

Similar Documents

Publication Publication Date Title
JP2013512877A5 (https=)
EP2506867B1 (en) Pharmaceutical compositions for the stimulation of stem cells.
RU2012120834A (ru) Фармацевтические композиции для стимулирования стволовых клеток
CN101448497B (zh) 包含硝唑尼特、替唑尼特、或其混合物的组合物在制备治疗丙型肝炎药物中的应用
Hefti Pharmacology of nerve growth factor and discovery of tanezumab, an anti-nerve growth factor antibody and pain therapeutic
US20040234572A1 (en) Preparation of sustained release pharmaceutical composition
JP2011529946A5 (https=)
JP2008545753A5 (https=)
JP2005512976A5 (https=)
CN1335765A (zh) 用于缓释蛋白质的多元醇/油悬浮剂
JP5313209B2 (ja) 歯周病と歯髄疾患の治療剤と治療方法
KR20070033966A (ko) Sns-595 및 그의 사용 방법
RU2007146986A (ru) Способы лечения опухолей головного мозга с использованием антител
JP2011528352A5 (https=)
US20210047653A1 (en) Compositions and methods for regulating a biological process
Mitsumoto et al. Neurotrophic factors and neuromuscular disease: I. General comments, the neurotrophin family, and neuropoietic cytokines
DE69738336T2 (de) Verwendung von keratinocyte growth factor-2
DE69714085T2 (de) Verwendung eines kgf-proteinproduktes und eines glp-2 proteinproduktes für die herstellung eines medikamentes
US20230233704A1 (en) Hydrogel composition and associated method of use
Mitsumoto et al. Neurotrophic factors and neuro‐muscular disease: II. GDNF, other neurotrophic factors, and future directions
AU773990B2 (en) Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors
KR20060008870A (ko) G-csf와 혈관 신생 작용을 갖는 인자의 병용
Hefti et al. Neurotrophic factors and neurodegenerative diseases
CN1250287C (zh) 一种重组腺病毒在脑缺血、创伤修复和组织粘连治疗中的应用
Sharvadze et al. Ifn/Rbv treatment induced anemia and its correction with epoetin alpha in patients with hepatitis C